SciELO - Scientific Electronic Library Online

 
vol.137 issue6Adipogenesis and osteoporosisVaccines against hepatitis A and B in Chile author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

LOPEZ B, Rodrigo; AESCHLIMANN D, Nicolás; CARVAJAL F, Claudia  and  LEMA F, Guillermo. Recombinant activated factor VII for perioperative bleeding. Rev. méd. Chile [online]. 2009, vol.137, n.6, pp.837-843. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872009000600016.

Recombinant activated factor VII (rFVIIa) is a new haemostatic drug, originally used for the treatment of patients with hemophilia A and B. At the present time it is used for other bleeding conditions such as the perioperative period. When used prophylactically there is a reduction in the number of bleeding episodes but no changes in the need for blood transfusion or other blood products. The adverse effects are arterial or venous thromboembolic events that are mostly related to the severity of the underlying disease of the patient and the concurrent administration of other haemostatic agents, rather than the use of rFVIIa. Its use is recommended when there is a persistent bleeding after the reposition of blood products and when surgical causes of bleeding have been discarded. The cost of the medication should also be considered before its use.

Keywords : Blood componenit transfusion; Factor VII a; Postoperative hemorrhage.

        · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License